Related Experiment Video
Updated: May 8, 2026
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
Peripheral Blood Biomarkers Predict Outcomes in Advanced Cancers Treated With Anti-PD-1 Therapy
Chunxia Feng1, Ping Li1, Qianhui Gu1
1Department of Radiotherapy and Oncology, Affiliated Kunshan Hospital of Jiangsu University, Kunshan, Jiangsu, China.
Objective:
PD-1 inhibitors are increasingly used in advanced cancers, but reliable biomarkers for predicting treatment response remain limited.
Methods:
In this retrospective cohort study, we analyzed 335 patients with stage IV cancers treated with anti-PD-1 therapy (The First People's Hospital of Kunshan, 2019-2025). A predictive model integrating peripheral blood markers and clinical factors was developed using logistic and Cox regression.
Results:
Histologic subtype, dNLR ≤ 3.18, AMC ≤ 0.48, and IL-6 ≤ 12.35 were independent prognostic factors for OS and PFS (multivariate HRs reported). Patients with ≥ 3 favorable factors had significantly better outcomes. The model showed high accuracy for 1-year survival prediction (AUC = 0.83) but limited performance beyond 3 years.
Conclusion:
This study proposes a clinically feasible biomarker-based tool to stratify PD-1 inhibitor responders, though further validation in prospective cohorts is needed.
More Related Videos
07:40Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
07:42Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021